Insider Buying: Opko Health CEO Phillip Md Et Al Frost Acquires 35,000 Shares of Stock (OPK)
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost acquired 35,000 shares of the company’s stock on the open market in a transaction dated Thursday, September 4th. The stock was purchased at an average price of $8.60 per share, for a total transaction of $301,000.00. Following the acquisition, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $17,306,442. The purchase was disclosed in a document filed with the SEC, which is available at this link.
Several analysts have recently commented on the stock. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday, August 13th. They now have a $10.50 price target on the stock, down previously from $11.00. Two investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $12.00.
Shares of Opko Health (NYSE:OPK) opened at 8.58 on Friday. Opko Health has a 52-week low of $7.32 and a 52-week high of $12.95. The stock’s 50-day moving average is $8.93 and its 200-day moving average is $8.89. The company’s market cap is $3.682 billion.
Opko Health (NYSE:OPK) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter last year, the company posted ($0.01) earnings per share. Opko Health’s revenue was down 1.3% compared to the same quarter last year.
OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with Analyst Ratings Network's FREE daily email newsletter.